# Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-safety-and-tolerability-of-a-monoclonal-antibody-to-proprotein/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael J. Koren,Robert C. Scott,Jae B. Kim,Beat Knüsel,Thomas Liu,Lei Lei,Michael A. Bolognese,Scott M. Wasserman |
| Citations | 362 |
| DOI | 10.1016/s0140-6736(12)61771-1 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2103647780 |
| PMID | 23141812 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Lei Lei](https://scholariq.org/researchers/lei-lei/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)

## Paper topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Atherosclerosis and Cardiovascular Diseases](https://scholariq.org/topics/atherosclerosis-and-cardiovascular-diseases/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.